漢商集團(600774.SH):漢商大健康擬與雲中私募共設基金管理公司
格隆匯8月11日丨漢商集團(600774.SH)公佈,為了充分發揮國家和地方引導基金的政策優勢、資源優勢和產業導向作用,以專業的投資管理團隊和先進的投資管理理念,為投資基金提供專業管理服務,並最終實現大健康產業的發展,公司全資子公司漢商大健康產業有限公司(簡稱“漢商大健康”)擬與武漢雲中私募基金管理有限公司(簡稱“雲中私募”)共同出資設立基金管理公司漢商大健康私募基金管理(武漢)有限公司,註冊資本人民幣1000萬元,從事私募股權投資基金管理、創業投資基金管理服務。
漢商大健康投資人民幣400萬元,佔基金管理公司40%股權,雲中私募投資人民幣600萬元,佔基金管理公司60%股權。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.